Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Our results show that as a therapy for subjects with unstable, labile diabetes or severe problems with hypoglycemia, islet transplantation can achieve consistent glucose values and alleviate these ...

Researchers from Tokyo Metropolitan University have uncovered a significant link between age-related diabetes and the loss of ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

Diabetes is a leading cause of global mortality and disability, and its economic burden is substantial. This Review focuses on type 2 diabetes, which makes up 90–95% of all diabetes cases. Type 2 ...

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...

The following is a summary of “Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Recent advances in immunotherapy have revealed a promising frontier in Type 1 diabetes treatment: outsmarting rather than ...

Among those who have had gestational diabetes, about 35% will develop type 2 diabetes within a decade. A new study led by Dr.